TG Therapeutics (TGTX) AI Stock Analysis

• Market Cap: $4.30B
• Dividend Yield: N/A
• Average Volume (3M): 2.27M
• Price to Earnings (P/E): 74.5
• Beta (1Y): 1.30
• Revenue Growth: 30.96%
• EPS Growth: -38.30%
• Country: US
• Employees: 352
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 0.17
• Shares Outstanding: 158,665,620
• 10 Day Avg. Volume: 3,973,397
• 30 Day Avg. Volume: 2,270,127
• PEG Ratio: 2.36
• Price to Book (P/B): 19.67
• Price to Sales (P/S): 13.29
• P/FCF Ratio: -107.84
• Enterprise Value/Market Cap: 1.36
• Enterprise Value/Revenue: 15.15
• Enterprise Value/Gross Profit: 17.32
• Enterprise Value/Ebitda: 83.54
• 1Y Price Target: $31.50
• Price Target Upside: 13.02% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

• Rating: 62 Neutral
• Price Target: $28.00 ▲(0.47% Upside)

TG Therapeutics' strong earnings call performance and financial recovery are offset by technical weaknesses and high valuation. The company's strategic progress with BRIUMVI is promising, but liquidity concerns and market momentum risks weigh on the overall score.

Positive Factors

International Expansion

Briumvi is now commercially available in additional countries in the EU, UK, Switzerland, and Australia, which could translate into incrementally larger royalty revenue in the quarters ahead.

Market Penetration

The company described seeing a meaningful increase in new prescribers and accounts, representing deeper penetration across both the academic and community treatment settings.

Revenue Growth

TG Therapeutics reported $120MM of US net Briumvi revenue, representing +11% Q/Q growth driven by a combination of new and repeat prescriptions.

Negative Factors

Competitive Challenges

Though the dosing frequency may offer an advantage over other subq options if approved, TG’s subq option is behind relative to approved subq options and may ultimately face an uphill battle in what is viewed as a growing section of the MS population.

Market Opportunity

Analyst reiterates Underperform and $11 price objective on, in their view, an overvalued long-term market opportunity for Briumvi with key challenges to competitive pillars ahead.

Research and Development Costs

The higher R&D spend this quarter, driven by manufacturing expenses for subq Briumvi, also raised some eyebrows.

TG Therapeutics Business Overview & Revenue Model

Company Description

TG Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for B-cell malignancies and autoimmune diseases. The company operates primarily in the biotechnology sector, focusing on targeted therapies that aim to improve patient outcomes. TG Therapeutics is known for its core products, including U2, an investigational treatment for chronic lymphocytic leukemia (CLL) and other hematologic malignancies, and TGR-1202, a selective inhibitor of PI3K delta, which is also in development for various cancers.

How the Company Makes Money

TG Therapeutics generates revenue primarily through the commercialization of its therapeutic products. The company earns money from product sales once its drugs receive regulatory approval and are marketed. Additionally, TG Therapeutics may benefit from milestone payments and royalties from strategic partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships can provide upfront payments, research funding, and share in the revenue generated from successful drug sales. The company is also involved in clinical trials and research collaborations, which can further contribute to its earnings through grants and funding from various health organizations.

TG Therapeutics Financial Statement Overview

Summary

TG Therapeutics demonstrates strong revenue and profit growth with improved balance sheet metrics. However, ongoing negative cash flow and historical instability pose risks, limiting the score.

Income Statement

TG Therapeutics has demonstrated strong revenue growth with a significant increase from $278,500 in 2022 to $386.4 million in TTM (Trailing-Twelve-Months). The gross profit margin improved to 87.4% in TTM, and net profit margin also rose to 10.1%, signaling enhanced operational efficiency. However, the past losses in earlier years indicate historical instability.

Balance Sheet

The company has managed to improve its financial health with positive stockholders' equity of $237.3 million in TTM. The debt-to-equity ratio is low at 0.038, indicating low leverage. However, the equity ratio of 36.1% suggests moderate reliance on liabilities, and past negative equity highlights previous financial distress.

Cash Flow

The operating cash flow remains negative at -$61 million in TTM, though free cash flow has shown improvement. The company's ability to convert net income into cash flow is limited, posing a risk to liquidity despite substantial financing activities that sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	386.39M	329.00M	233.66M	2.79M	6.69M	152.00K
Gross Profit	337.80M	290.52M	219.11M	2.52M	5.90M	-222.00K
EBITDA	70.06M	49.90M	26.10M	-187.63M	-341.97M	-272.68M
Net Income	39.15M	23.38M	12.67M	-203.83M	-355.55M	-285.88M
Balance Sheet
Total Assets	656.69M	577.69M	329.59M	193.57M	379.63M	625.64M
Cash, Cash Equivalents and Short-Term Investments	276.24M	311.00M	217.51M	174.08M	350.30M	605.43M
Total Debt	254.58M	254.38M	110.80M	83.06M	79.05M	41.98M
Total Liabilities	419.40M	355.33M	169.09M	134.99M	142.48M	106.29M
Stockholders Equity	237.29M	222.36M	160.50M	-1.53B	-1.33B	519.35M
Cash Flow
Free Cash Flow	-61.09M	-40.56M	-31.41M	-176.18M	-296.04M	-214.86M
Operating Cash Flow	-61.02M	-40.52M	-31.41M	-176.17M	-295.63M	-214.51M
Investing Cash Flow	-4.71M	-1.04M	-50.65M	-20.01M	-332.00K	-24.51M
Financing Cash Flow	122.42M	128.53M	72.70M	-391.00K	41.42M	679.83M

TG Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 27.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TGTX, the sentiment is Negative. The current price of 27.87 is below the 20-day moving average (MA) of 33.09, below the 50-day MA of 35.55, and below the 200-day MA of 34.22, indicating a bearish trend. The MACD of -2.70 indicates Positive momentum. The RSI at 30.16 is Neutral, neither overbought nor oversold. The STOCH value of 16.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TGTX.

TG Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	62 Neutral	$4.30B	74.48	26.63%	―	30.96%	-38.30%
JAZZ	60 Neutral	$6.87B	15.58	-10.84%	―	4.52%	-205.13%
RYTM	56 Neutral	$6.41B	―	-1334.54%	―	53.55%	30.87%
IONS	54 Neutral	$6.60B	―	-59.83%	―	16.04%	30.61%
AXSM	53 Neutral	$5.25B	―	-280.68%	―	69.83%	22.16%
Sector *	51 Neutral	$7.43B	-0.36	-45.45%	2.27%	22.98%	-2.34%
NUVL	43 Neutral	$5.52B	―	-43.55%	―	―	-76.16%

TG Therapeutics Corporate Events

TG Therapeutics Approves Key Proposals at Annual Meeting

On June 12, 2025, TG Therapeutics, Inc. held its Annual Meeting where stockholders representing 74.58% of the outstanding shares were present. All proposals, including the election of six directors, ratification of KPMG LLP as the independent auditor, approval of executive compensation, and amendment to the 2022 Incentive Plan, were approved, potentially impacting the company’s governance and financial strategies.

The most recent analyst rating on (TGTX) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on TG Therapeutics stock, see the TGTX Stock Forecast page.